Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet

Koji Nagao, Susumu Yoshida, Hideaki Nakagiri, Masanobu Sakono, Masao Sato, Katsumi Imaizumi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Gemfibrozil is a widely used drug prescribed to elevate serum high-density lipoprotein (HDL) cholesterol levels and lower triacylglycerols. The present study was done to determine if the drug would alleviate hypercholesterolemia in exogenously hypercholesterolemic (ExHC) rats. In the drug-treated ExHC rats, the serum non-HDL cholesterol levels were lowered and the ratio of the non HDL cholesterol to serum triacylglycerols was decreased to the extent seen in the drug-treated SD rats. Liver cholesterol and triacylglycerols were lowered in the drug-treated rats. There was also an increase in fecal excretion of neutral sterols and bile acids, particularly chenodeoxycholic and β-muricholic acids. The drug elevated cholesterol 7α-hydroxylase activity and mRNA abundance and acyl-CoA cholesterol acyltransferase activity in the liver, but did not influence low-density lipoprotein receptor mRNA level in the liver. Thus, gemfibrozil is effective in alleviating hypercholesterolemia in exogenously hypercholesterolemic rats, by partitioning hepatic cholesterol into biliary excretion. Copyright (C) 1998 Elsevier Science Inc.

Original languageEnglish
Pages (from-to)579-586
Number of pages8
JournalComparative Biochemistry and Physiology - B Biochemistry and Molecular Biology
Volume120
Issue number3
DOIs
Publication statusPublished - Sep 1 1998

Fingerprint

Gemfibrozil
Nutrition
Rats
Cholesterol
Diet
Hypercholesterolemia
Pharmaceutical Preparations
Liver
Triglycerides
HDL Cholesterol
Serum
Cholesterol 7-alpha-Hydroxylase
Sterol O-Acyltransferase
Chenodeoxycholic Acid
Messenger RNA
LDL Receptors
Sterols
Bile Acids and Salts
lipoprotein cholesterol

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Physiology
  • Molecular Biology

Cite this

Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet. / Nagao, Koji; Yoshida, Susumu; Nakagiri, Hideaki; Sakono, Masanobu; Sato, Masao; Imaizumi, Katsumi.

In: Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, Vol. 120, No. 3, 01.09.1998, p. 579-586.

Research output: Contribution to journalArticle

@article{d769ae68e2d64b69b142840c5d71b620,
title = "Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet",
abstract = "Gemfibrozil is a widely used drug prescribed to elevate serum high-density lipoprotein (HDL) cholesterol levels and lower triacylglycerols. The present study was done to determine if the drug would alleviate hypercholesterolemia in exogenously hypercholesterolemic (ExHC) rats. In the drug-treated ExHC rats, the serum non-HDL cholesterol levels were lowered and the ratio of the non HDL cholesterol to serum triacylglycerols was decreased to the extent seen in the drug-treated SD rats. Liver cholesterol and triacylglycerols were lowered in the drug-treated rats. There was also an increase in fecal excretion of neutral sterols and bile acids, particularly chenodeoxycholic and β-muricholic acids. The drug elevated cholesterol 7α-hydroxylase activity and mRNA abundance and acyl-CoA cholesterol acyltransferase activity in the liver, but did not influence low-density lipoprotein receptor mRNA level in the liver. Thus, gemfibrozil is effective in alleviating hypercholesterolemia in exogenously hypercholesterolemic rats, by partitioning hepatic cholesterol into biliary excretion. Copyright (C) 1998 Elsevier Science Inc.",
author = "Koji Nagao and Susumu Yoshida and Hideaki Nakagiri and Masanobu Sakono and Masao Sato and Katsumi Imaizumi",
year = "1998",
month = "9",
day = "1",
doi = "10.1016/S0305-0491(98)10049-4",
language = "English",
volume = "120",
pages = "579--586",
journal = "Comparative biochemistry and physiology. B, Comparative biochemistry",
issn = "1096-4959",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Gemfibrozil reduces non-high-density lipoprotein cholesterol in exogenously hypercholesterolemic (ExHC) rats fed a high-cholesterol diet

AU - Nagao, Koji

AU - Yoshida, Susumu

AU - Nakagiri, Hideaki

AU - Sakono, Masanobu

AU - Sato, Masao

AU - Imaizumi, Katsumi

PY - 1998/9/1

Y1 - 1998/9/1

N2 - Gemfibrozil is a widely used drug prescribed to elevate serum high-density lipoprotein (HDL) cholesterol levels and lower triacylglycerols. The present study was done to determine if the drug would alleviate hypercholesterolemia in exogenously hypercholesterolemic (ExHC) rats. In the drug-treated ExHC rats, the serum non-HDL cholesterol levels were lowered and the ratio of the non HDL cholesterol to serum triacylglycerols was decreased to the extent seen in the drug-treated SD rats. Liver cholesterol and triacylglycerols were lowered in the drug-treated rats. There was also an increase in fecal excretion of neutral sterols and bile acids, particularly chenodeoxycholic and β-muricholic acids. The drug elevated cholesterol 7α-hydroxylase activity and mRNA abundance and acyl-CoA cholesterol acyltransferase activity in the liver, but did not influence low-density lipoprotein receptor mRNA level in the liver. Thus, gemfibrozil is effective in alleviating hypercholesterolemia in exogenously hypercholesterolemic rats, by partitioning hepatic cholesterol into biliary excretion. Copyright (C) 1998 Elsevier Science Inc.

AB - Gemfibrozil is a widely used drug prescribed to elevate serum high-density lipoprotein (HDL) cholesterol levels and lower triacylglycerols. The present study was done to determine if the drug would alleviate hypercholesterolemia in exogenously hypercholesterolemic (ExHC) rats. In the drug-treated ExHC rats, the serum non-HDL cholesterol levels were lowered and the ratio of the non HDL cholesterol to serum triacylglycerols was decreased to the extent seen in the drug-treated SD rats. Liver cholesterol and triacylglycerols were lowered in the drug-treated rats. There was also an increase in fecal excretion of neutral sterols and bile acids, particularly chenodeoxycholic and β-muricholic acids. The drug elevated cholesterol 7α-hydroxylase activity and mRNA abundance and acyl-CoA cholesterol acyltransferase activity in the liver, but did not influence low-density lipoprotein receptor mRNA level in the liver. Thus, gemfibrozil is effective in alleviating hypercholesterolemia in exogenously hypercholesterolemic rats, by partitioning hepatic cholesterol into biliary excretion. Copyright (C) 1998 Elsevier Science Inc.

UR - http://www.scopus.com/inward/record.url?scp=0031864456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031864456&partnerID=8YFLogxK

U2 - 10.1016/S0305-0491(98)10049-4

DO - 10.1016/S0305-0491(98)10049-4

M3 - Article

C2 - 9787818

AN - SCOPUS:0031864456

VL - 120

SP - 579

EP - 586

JO - Comparative biochemistry and physiology. B, Comparative biochemistry

JF - Comparative biochemistry and physiology. B, Comparative biochemistry

SN - 1096-4959

IS - 3

ER -